Related Experiment Video
Updated: Jun 13, 2026
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
The AIM4 Next Step study: Comparing inhaled corticosteroid dose escalation to dupilumab in patients with uncontrolled
William W Busse1, Melissa Iammatteo2, Mena Soliman2
1UW Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wis.
Background:
The Global Initiative for Asthma recommends patients with asthma uncontrolled on medium-dose inhaled corticosteroid (ICS) plus long-acting β2-agonist (LABA) therapy to first escalate their ICS dose before considering add-on biologic therapy despite acknowledging that high-dose ICS provides little additional benefit for most patients and carries an increased risk of adverse effects. Dupilumab, an IL-4Rα antagonist that inhibits signaling of IL-4 and IL-13, has demonstrated efficacy in patients with uncontrolled moderate-to-severe asthma and type 2 inflammation.
Objective:
The AIM4: Next Step study will evaluate whether earlier intervention with dupilumab provides clinical benefit compared to escalation to high-dose ICS/LABA.
Methods:
AIM4: Next Step (NCT06572228) is a randomized, double-blind, active-controlled study enrolling approximately 250 adolescents and adults with type 2 inflammatory asthma uncontrolled with medium-dose ICS/LABA treatment. Patients will be randomized 1:1 to receive dupilumab 300 mg every 2 weeks plus medium-dose ICS/LABA or placebo plus high-dose ICS/LABA.
Results:
The primary end point is the annualized rate of severe asthma exacerbations over 52 weeks. Key secondary end points include change from baseline in prebronchodilator forced expiratory volume in 1 second at week 12, annualized systemic corticosteroid exposure for exacerbations, and asthma control at week 12 based on 5-item Asthma Control Questionnaire.
Conclusion:
AIM4: Next Step is the first study designed to address an important gap in asthma management by directly comparing ICS dose escalation versus early biologic intervention with dupilumab in patients with uncontrolled type 2 inflammatory asthma. Findings may inform future treatment strategies for patients whose asthma remains uncontrolled despite ICS/LABA.
Related Concept Videos
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:26Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.